COLL vs PFE · P/E 17, rev $181.9M vs P/E 20, rev $62.58B
Collegium Pharmaceutical Inc (COLL) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the COLL and PFE stock pages for the full models.
Not investment advice.